利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.05 秒)

    Inhibitors of interleukin-1&bgr; converting enzyme
    6.
    发明授权
    Inhibitors of interleukin-1&bgr; converting enzyme 失效
    白细胞介素-1β转换酶抑制剂

    公开(公告)号：US06350741B1

    公开(公告)日：2002-02-26

    申请号：US09326494

    申请日：1999-06-04

    申请人： Julian M. C. Golec ,  David J. Lauffer ,  David J. Livingston ,  Michael D. Mullican ,  Philip L. Nyce ,  Andrea L. C. Robidoux ,  Marion W. Wannamaker

    发明人： Julian M. C. Golec ,  David J. Lauffer ,  David J. Livingston ,  Michael D. Mullican ,  Philip L. Nyce ,  Andrea L. C. Robidoux ,  Marion W. Wannamaker

    IPC分类号： A61K3155

    CPC分类号： C07K5/06139 ,  A61K38/00 ,  C07K5/0202 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/475

    摘要： The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme (“ICE”). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-&ggr; inducing factor-(IGIF), or interferon-&ggr;-(“IFN-&ggr;”) mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting ICE activity and decreasing IGIF production and IFN-&ggr; production and methods for treating interleukin-1, apoptosis- and interferon-&ggr;-mediated diseases using the compounds and compositions of this invention. This invention also relates to methods of preparing the compounds of this invention.

    摘要翻译： 本发明涉及作为白细胞介素-1β转换酶（“ICE”）抑制剂的新型化合物。 本发明还涉及包含这些化合物的药物组合物。 本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可有利地用作抗白细胞介素-1-（“IL-1”），细胞凋亡，干扰素-γ诱导因子（IGIF） 或“干扰素-γ”（“IFN-γ”）介导的疾病，包括炎性疾病，自身免疫性疾病，破坏性骨病，增殖性疾病，感染性疾病和退行性疾病。 本发明还涉及使用本发明的化合物和组合物来抑制ICE活性和降低IGIF产生和IFN-γ产生的方法以及用于治疗白细胞介素-1，凋亡和干扰素-γ介导的疾病的方法。 本发明还涉及制备本发明化合物的方法。

    Inhibitors of interleukin-1&bgr; converting enzyme
    9.
    发明授权
    Inhibitors of interleukin-1&bgr; converting enzyme 失效
    白细胞介素-1β转换酶抑制剂

    公开(公告)号：US06573259B2

    公开(公告)日：2003-06-03

    申请号：US10035850

    申请日：2001-10-23

    申请人： Julian M. C. Golec ,  David J. Lauffer ,  David J. Livingston ,  Michael D. Mullican ,  Mark A. Murcko ,  Philip L. Nyce ,  Andrea L. C. Robidoux ,  Marion W. Wannamaker

    发明人： Julian M. C. Golec ,  David J. Lauffer ,  David J. Livingston ,  Michael D. Mullican ,  Mark A. Murcko ,  Philip L. Nyce ,  Andrea L. C. Robidoux ,  Marion W. Wannamaker

    IPC分类号： A61K3155

    CPC分类号： C07K5/0821 ,  A61K38/00 ,  C07K5/0202 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/475

    摘要： The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme (“ICE”). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-&ggr; inducing factor-(IGIF), interferon-&ggr;-(“IFN-&ggr;”) mediated diseases, excess dietary alcohol intake diseases, or viral diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting ICE activity and decreasing IGIF production and IFN-&ggr; production and methods for treating interleukin-1, apoptosis- and interferon-&ggr;-mediated diseases using the compounds and compositions of this invention. This invention also relates to methods of preparing the compounds of this invention.

    摘要翻译： 本发明涉及作为白细胞介素-1β转换酶（“ICE”）抑制剂的新型化合物。 本发明还涉及包含这些化合物的药物组合物。 本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可有利地用作抗白细胞介素-1-（“IL-1”），细胞凋亡，干扰素-γ诱导因子（IGIF） 干扰素-γ-（“IFN-γ”）介导的疾病，过度饮食酒精摄入疾病或病毒性疾病，包括炎性疾病，自身免疫疾病，破坏性骨病，增殖性疾病，感染性疾病和退行性疾病。 本发明还涉及使用本发明的化合物和组合物来抑制ICE活性和降低IGIF产生和IFN-γ产生的方法以及用于治疗白细胞介素-1，凋亡和干扰素-γ介导的疾病的方法。 本发明还涉及制备本发明化合物的方法。